These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25073736)

  • 1. Impact of antiviral treatment on survival in HCV-positive liver recipients.
    Wawrzynowicz-Syczewska M; Zeair S; Andruszkiewicz A; Bartoszewicz K; Sławiński J; Laurans Ł; Jurczyk K; Karpińska E; Socha Ł; Duczkowska M; Parczewski M
    Ann Transplant; 2014 Jul; 19():367-72. PubMed ID: 25073736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR
    Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
    Pillai AA; Lee VS; Wang E; Rinella ME; Levitsky J
    Transplant Proc; 2010 Nov; 42(9):3647-51. PubMed ID: 21094833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.
    Duvoux C; Villamil F; Renner EL; Grazi GL; Firpi RJ; Pageaux G; Mulhaupt B; Schirm F; Rauer B; Bernhardt P; Levy G
    Ann Transplant; 2015 Jan; 20():25-35. PubMed ID: 25588713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
    Campos-Varela I; Castells L; Esteban JI; Bes M; Rodríguez-Frías F; Sapisochin G; Allende H; Charco R; Esteban R
    Transplantation; 2012 Feb; 93(4):450-3. PubMed ID: 22262129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience.
    Jain A; Sharma R; Ryan C; Safadjou S; Kashyap R; Mantry P; Maliakkal B; Orloff M
    Clin Transplant; 2010; 24(1):104-11. PubMed ID: 19239480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCV infection is associated with lower survival in simultaneous liver kidney transplant recipients in the United States.
    Perumpail RB; Wong RJ; Scandling JD; Ha le D; Todo T; Bonham CA; Saab S; Younossi ZM; Ahmed A
    Clin Transplant; 2015 Oct; 29(10):920-6. PubMed ID: 26205329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
    Liu CJ; Chu YT; Shau WY; Kuo RN; Chen PJ; Lai MS
    Gut; 2014 Mar; 63(3):506-14. PubMed ID: 23676440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation.
    Picciotto FP; Tritto G; Lanza AG; Addario L; De Luca M; Di Costanzo GG; Lampasi F; Tartaglione MT; Marsilia GM; Calise F; Cuomo O; Ascione A
    J Hepatol; 2007 Mar; 46(3):459-65. PubMed ID: 17196700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of cryoglobulinemia on the antiviral therapy in patients with chronic hepatitis C].
    Fan XH; Wang LF; Liu LC; Yao Y; Shan Y; Lu HY; Wu CH; Xu XY; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):721-5. PubMed ID: 22409840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
    Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
    J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.
    Giusto M; Rodriguez M; Navarro L; Rubin A; Aguilera V; San-Juan F; Ortiz C; López-Andujar R; Prieto M; Berenguer M
    Liver Transpl; 2011 Nov; 17(11):1318-27. PubMed ID: 21761553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient.
    Montalbano M; Pasulo L; Sonzogni A; Remuzzi G; Colledan M; Strazzabosco M
    J Clin Gastroenterol; 2007 Feb; 41(2):216-20. PubMed ID: 17245223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.